President-elect Trump's nomination of Robert F. Kennedy Jr. for HHS Secretary raises concerns due to his views on the pharmaceutical industry. Analysts like Chris Meekins believe the sell-off in pharmaceutical stocks may be an overreaction. Watch more on Asking for a Trend for expert insights.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing